Market Watch: Gerdau S.A. (NYSE:GGB), Oncothyreon Inc (NASDAQ:ONTY), Zebra Technologies Corp. (NASDAQ:ZBRA), SM Energy Company (NYSE:SM), CAMAC Energy, Inc. (NYSEMKT:CAK)

Standard & Poor’s Ratings Services affirmed its ‘BBB-‘ global scale and ‘brAAA’ Brazil national scale ratings on Gerdau S.A. (NYSE:GGB). We are also affirming our ‘BBB-‘ rating on Gerdau Ameristeel Corp., Gerdau’s North American subsidiary. The outlooks on all the ratings are stable. Gerdau S.A. (NYSE:GGB) belongs to Basic Materials sector. Its net profit margin is 3.50% and weekly performance is -20.36%. On last trading … Continue reading Market Watch: Gerdau S.A. (NYSE:GGB), Oncothyreon Inc (NASDAQ:ONTY), Zebra Technologies Corp. (NASDAQ:ZBRA), SM Energy Company (NYSE:SM), CAMAC Energy, Inc. (NYSEMKT:CAK)

Mark Doerr12/1512/15

Trader’s Recap: Hertz Global Holdings, Inc. (NYSE:HTZ), TheStreet, Inc. (NASDAQ:TST), Douglas Dynamics, Inc. (NYSE:PLOW), Balchem Corp. (NASDAQ:BCPC), Oncothyreon Inc (NASDAQ:ONTY)

Hertz Global Holdings (NYSE:HTZ) CEO John P. Tague bought 84,200 shares of the stock on the open market in a transaction that occurred on Monday, November 24th. The stock was purchased at an average cost of $24.11 per share, with a total value of $2,030,062.00. Hertz Global Holdings, Inc. (NYSE:HTZ) belongs to Services sector. Its net profit margin is 6.50% and weekly performance is -0.08%. … Continue reading Trader’s Recap: Hertz Global Holdings, Inc. (NYSE:HTZ), TheStreet, Inc. (NASDAQ:TST), Douglas Dynamics, Inc. (NYSE:PLOW), Balchem Corp. (NASDAQ:BCPC), Oncothyreon Inc (NASDAQ:ONTY)

Mark DeFrance12/0812/08

Losers at NASDAQ: Mandalay Digital Group (NASDAQ:MNDL), Dixie Group Inc (NASDAQ:DXYN), Oncothyreon (NASDAQ:ONTY), Astrotech (NASDAQ:ASTC), LiveDeal (NASDAQ:LIVE)

Mandalay Digital Group, Inc. (NASDAQ:MNDL), a leading provider of mobile technology solutions, announced on 02 June 2014 that it has expanded its relationship with SingTel to include direct billing connectivity with its DT Pay product. Mandalay Digital Group Inc (NASDAQ:MNDL) stock performance was -5.32% in last session and finished the day at $3.56. Traded volume was 203,024.00million shares in the last session and the average … Continue reading Losers at NASDAQ: Mandalay Digital Group (NASDAQ:MNDL), Dixie Group Inc (NASDAQ:DXYN), Oncothyreon (NASDAQ:ONTY), Astrotech (NASDAQ:ASTC), LiveDeal (NASDAQ:LIVE)

Jason Knox06/1206/12

Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Corcept Therapeutics (NASDAQ:CORT) Director Longitude Venture Partners L.P sold 250,000 shares of the company’s stock on the open market in a transaction dated Friday, May 2nd. The stock was sold at an average price of $4.11, for a total value of $1,027,500.00. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 5.06% percent to $ 4.15 yesterday on volume of 319,314 shares. The intra-day range of the stock was … Continue reading Healthcare Watch List: Oncothyreon (NASDAQ:ONTY), Corcept Therapeutics Incorporated (NASDAQ:CORT), Aastrom Biosciences (NASDAQ:ASTM), Durata Therapeutics (NASDAQ:DRTX)

Colin Pettis05/0605/06

Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported a fourth-quarter 2013 loss of 32 cents per share (excluding one-time expenses), narrower than the year-ago loss of 43 cents per share and the Zacks Consensus Estimate of a loss of 40 cents. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) stock performance was -6.08% in last session and finished the day at $1.70. Traded volume was 1.35million shares in the last session and … Continue reading Top Losers: AVEO Pharmaceuticals (NASDAQ:AVEO), Santander Mexico Fincl Gp SAB (NYSE:BSMX), Oncothyreon Inc (NASDAQ:ONTY), Omeros Corporation (NASDAQ:OMER)

Chris Lewis03/1703/17

Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor Inc. (NASDAQ:XNCR) stock performance was -1.58% in last session and finished the day at $13.68. Traded volume was 99,904.00 shares … Continue reading Biotech Overbought Socks: Xencor Inc. (NASDAQ:XNCR), Albany Molecular Research (NASDAQ:AMRI), Oncothyreon (NASDAQ:ONTY), OXiGENE Inc. (NASDAQ:OXGN)

Jayne Crisman03/1403/14